117 related articles for article (PubMed ID: 34826742)
1. Clinicopathological features and genomic profiles of hepatoid adenocarcinoma of the lung: Report of four cases.
Sun H; Li X; Zhang J; Liu Y
Pathol Res Pract; 2022 Jan; 229():153652. PubMed ID: 34826742
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
3. Clinical characteristics of Hepatoid adenocarcinoma of the lung: Four case reports and literature review.
Zhuansun Y; Bian L; Zhao Z; Du Y; Chen R; Lin L; Li J
Cancer Treat Res Commun; 2021; 29():100474. PubMed ID: 34656923
[TBL] [Abstract][Full Text] [Related]
4. Hepatoid adenocarcinoma of lung: A diagnostic challenge - Series of six cases with histopathological, predictive molecular and PD.L1 assessment.
Pasricha S; Grover S; Kamboj M; Bansal D; Batra U; Gupta G; Sharma A; Durga G; Jajodia A; B Koyyala VP; Mehta A
Indian J Pathol Microbiol; 2021; 64(1):128-131. PubMed ID: 33433422
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile.
Hou H; Zhu H; Zhao H; Yan W; Wang Y; Jiang M; Liu B; Liu D; Zhou N; Zhang C; Li P; Chang L; Guan Y; Wang Z; Zhang X; Li Z; Fang B; Zhang X
Oncologist; 2018 Sep; 23(9):1008-1015. PubMed ID: 29700208
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
7. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations.
Geng H; Li S; Guo Y; Yan F; Han Y; Xu M; Cui Y
Cancer Biomark; 2020; 27(4):525-532. PubMed ID: 32083571
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
[TBL] [Abstract][Full Text] [Related]
10. Disruptive and Truncating TP53 Mutations Are Associated with African-Ancestry and Worse Prognosis in Brazilian Patients with Lung Adenocarcinoma.
Cavagna RO; Pinto IA; Escremim de Paula F; Berardinelli GN; Sant'Anna D; Santana I; da Silva VD; Da Silva ECA; Miziara JE; Mourão Dias J; Antoniazzi A; Jacinto A; De Marchi P; Molina-Vila MA; Ferro Leal L; Reis RM
Pathobiology; 2023; 90(5):344-355. PubMed ID: 37031678
[TBL] [Abstract][Full Text] [Related]
11. Hepatoid Adenocarcinoma of the Lung.
Li M; Fan Y; Lu H
Technol Cancer Res Treat; 2021; 20():15330338211057983. PubMed ID: 34816785
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
13. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
14. Next generation sequencing in lung cancer: An initial experience from India.
Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
[TBL] [Abstract][Full Text] [Related]
15. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.
Zhou J; Sanchez-Vega F; Caso R; Tan KS; Brandt WS; Jones GD; Yan S; Adusumilli PS; Bott M; Huang J; Isbell JM; Sihag S; Molena D; Rusch VW; Chatila WK; Rekhtman N; Yang F; Ladanyi M; Solit DB; Berger MF; Schultz N; Jones DR
Clin Cancer Res; 2019 Dec; 25(24):7475-7484. PubMed ID: 31455678
[TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
18. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
19. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma.
Nassereddine H; Sannier A; Brosseau S; Rodier JM; Khalil A; Msika S; Danel C; Couvelard A; Théou-Anton N; Cazes A
Pathol Oncol Res; 2020 Oct; 26(4):2795-2800. PubMed ID: 31407221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
